Rewriting the Rules of Antibody Drug Design
About this episode
Angela Hwang discusses Metaphore Biotechnologies' innovative approach to antibody drug design using live-cell experiments and machine learning.
Most marketed antibodies work as antagonists, simply shutting off a receptor, even though many immune, metabolic, and cancer pathways require more nuanced control. Metaphore Biotechnologies' function‑first platform combines live-cell experiments with machine learning to read how receptors and binding partners behave in living systems, distill those complex dynamics into the key functional features, and then design functional antibodies that agonize, bias, or multi-target pathways from the outset. Metaphore CEO Angela Hwang discusses how the company is using this approach to open up difficult or previously undruggable targets, generate medicines with better profiles, and give drug developers greater control over complex signaling than traditional drug development approaches allow.
More episodes of The Bio Report
- Mapping Cellular Stress Biology to Tackle Undruggable Targets
- Turning Abandoned Drugs into Breakthroughs
- Targeting Cancer Survival Genes in Solid Tumors
Explore listener stats, chart rankings, contacts and more on the The Bio Report podcast page.